BIND Biosciences, Inc. to Present at Lazard Capital Markets Healthcare Conference
10/24/2012 9:17:17 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that Andrew Hirsch, BIND’s CFO, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference at 9:00 a.m. ET on Wednesday, November 14, 2012, at the Pierre Hotel, New York.
comments powered by